A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Interpretation of nanoparticle PK results can be markedly influenced by differing PK metrics selected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Comparisons between %ID in tumor and traditional PK metrics for all datasets (i.e., all types of nanoparticles). Correlation plots for all datasets between %ID in tumor (per Wilhelm et al.) and AUCtumor/AUCblood ratio (%) (A), RDI-OT AUCtumor (B), and tumor Cmax (C). Plots are shown with all datasets (i, outliers shown as □) and with outliers excluded (ii). There was no relationship between %ID in tumor and AUCtumor/AUCblood ratio (%) [ρ = 0.183 all data (AD); ρ = 0.151 excluding outliers (EO)] and a weak relationship between %ID in tumor and RDI-OT AUCtumor (ρ = 0.319 AD; ρ = 0.289 EO). There was a moderate relationship between %ID in tumor and the tumor Cmax (ρ = 0.562 AD; ρ = 0.572 EO).](https://figures.cochat.ai/paper-figures/800c7ec305d0438ea04d8675852da227/a-reanalysis-of-nanoparticle-tumor-delivery-using-classical-pharmacokinetic-figure-1.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The conclusion was that the %ID in tumor was poorly correlated with the standard PK metrics which describe nanoparticle tumor delivery (AUCtumor/AUCblood ratio).”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [244]
The cited source says what the claim attributes to it.
In the citing paper
“The relative tumor delivery of nanoparticles was ~100-fold greater as assessed by the standard AUCtumor/AUCblood ratio than by %ID in tumor.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [244]
The cited source says what the claim attributes to it.
In the citing paper
“A recent reanalysis by Price et al., based on the same dataset, has cast major doubt on the validity of Wilhelm et al. conclusions [244].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [244]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218 · cited 3×
“(19) However, the conclusions of the study by Wilhelm et al.”
BackgroundResultStatistics corner: A guide to appropriate use of correlation coefficient in medical research.
(2012) · Europe PMC (PubMed Central) · Cited by 4,239
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485
Self-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Liu, J., Liao, S., Diop-Frimpong, B., Chen, W., Goel, S., Naxerova, K., Ancukiewicz, M., Boucher, Y., Jain, R. K., & Xu, L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117610109 · Cited by 330
Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance
Zamboni, W. C., Torchilin, V., Patri, A. K., Hrkach, J., Stern, S., Lee, R., Nel, A., Panaro, N. J., & Grodzinski, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2938 · Cited by 275
Self-citationA Safe‐by‐Design Strategy towards Safer Nanomaterials in Nanomedicines
Yan, L., Zhao, F., Wang, J., Zu, Y., Gu, Z., & Zhao, Y. (2019) · Advanced Materials · doi:10.1002/adma.201805391 · Cited by 183 · cited 1×
“In 2017 alone, there were more than 300 nanomedicine patent filings, with more than half related to drug delivery (3).”
BackgroundConcept and Clinical Evaluation of Carrier-Mediated Anticancer Agents
Zamboni, W. C. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0180 · Cited by 173 · cited 1×
“Examples of various types of NPs include liposomes, polymeric micelles, fullerenes, carbon nanotubes, quantum dots, nanoshells, polymers, dendrimers, and conjugates, including antibody-drug conjugates (9).”
BackgroundSelf-citation
Cited by
Items 101–140 of 140
Enhancing the Safety of Nanoparticles in Medicine: Highlights of Progress and Critical Objectives
Ramos, T. M., Alencar, L. M. R., Ricci‐Júnior, E., Fechine, P. B. A., & Santos‐Oliveira, R. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s559584 · Cited by 3
Li, F., Zhu, Y., Qi, D., Chen, C., Li, Z., Cao, Z., & Yang, X. (2024) · Nano Research · doi:10.26599/nr.2025.94907164 · Cited by 2
Delivery strategies for cancer vaccines and immunoadjuvants
Graham-Gurysh, E. G., Carpenter, B. W., Beck, W. A., Varma, D. M., Vincent, B. G., Bachelder, E. M., & Ainslie, K. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00014-2 · Cited by 2
It takes Two: Advancing cancer treatment with two-step nanoparticle delivery
Komedchikova, E. N., Kolesnikova, O. A., Obozina, A. S., Antonova, A. O., Dukat, A. M., Fedotova, P. A., Khardikova, D. S., Sokol, D. V., Shimanskaia, I. O., Svetlakova, A. V., et al. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151921 · Cited by 1
Nanocarriers for Chemotherapy and Drug Delivery
Latif, A., Maryam, L., Khan, A. A., & Basit, M. A. (2025) · Series in bioengineering · doi:10.1007/978-981-95-0457-2_5 · Cited by 1
Antisense oligonucleotide-based switches for conditional translation of synthetic mRNA
Combes, F., Pettersson, F. J., & Bui, T.-H. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102729 · Cited by 1
“5,6 An alternative strategy that is gaining momentum involves the implementation of molecular switches which modulate the ability of ribosomes to translate a synthetic mRNA into proteins when a specific condition is met.”
Jankowska, J., Szeleszczuk, Ł., & Pisklak, D. M. (2026) · Biology · doi:10.3390/biology15171550 · Cited by 1
“Reanalysis of the underlying murine pharmacokinetic data using conventional exposure-based parameters demonstrated that the interpretation of nanoparticle tumor delivery can vary markedly depending on the pharmacokinetic metric selected [40].”
Vasalou, C., Ferguson, D., Li, W., Muse, V., Gibbons, F. D., Sonzini, S., Zhang, G., Pop-Damkov, P., Gangl, E. T., Balachander, S. B., et al. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00715 · Cited by 1
Lipid nanoparticles loaded with anticancer bioactives: state of the art
Faria, G. N. F., Bhavsar, D., Munshi, A., & Ramesh, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15401-0.00017-8 · Cited by 2
Nahas, H., Saba, S., METLEJ, P., Ribault, C., Vène, É., Lepareur, N., Cammas‐Marion, S., & Loyer, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.26.605135 · Cited by 1
Antonio, L. C. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.76.2023.tde-15032023-145008
Zhang, Y., Xia, Q., Wu, T., He, Z., Li, Y., Li, Z., Hou, X., He, Y., Ruan, S., Wang, Z., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15178967
A Toolbox for the Personalization of Plasmonic Photothermal Therapy in Orthotopic Mouse Tumor ModelsPreprint
Fernández-Esteberena, P. R., Vilches, C., Morales-Dalmau, J., Mireles, M., Martínez‐Lozano, M., de Miguel, I., Casanovas, O., Quidant, R., & Durduran, T. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.02.651947
“For our particular formulation, the GNR–PEG concentration delivered to the tumor by 24 h after injection was in line with literature reviews [73] and similar to the concentration in the kidney, in agreement with two-photon microscopy measurements previously published for this model [50].”
Zhang, Y., Xia, Q., Wu, T., He, Z., Li, Y., Li, Z., Hou, X., He, Y., Ruan, S., Wang, Z., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15178964
Marasini, R. (2020) · K-State Research Exchange (Kansas State University) · Cited by 1
Precision nanomedicines in glioblastoma therapy and challenges remain
Mazahir, F. (2026) · Next Nanotechnology · doi:10.1016/j.nxnano.2026.100431 · Cited by 1
Zhu, W., Wang, C., Sun, M., & Tao, J. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126960
Ali, H., Farooq, M., & Shah, U. (2026) · Pharmacophore · doi:10.51847/bacfkkxgas
Demianchuk, N. R., Пазюк, Л., & Бузинська, Н. (2026) · Перспективи та інновації науки · doi:10.52058/2786-4952-2026-5(63)-2683-2697
Yang, Z.-H., Huang, Q.-L., Luo, L., Wu, X.-X., Nie, S.-W., & Xu, M. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.121133
Odei-Mensah, B., Adeyemi, S. A., & Choonara, Y. E. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104422
Niazi, S. K. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18081019
“…employing conventional pharmacokinetic endpoints revealed that the percentage of injected dose within the tumor demonstrated poor correlation with the area-under-curve ratio between tumor and blood, thereby indicating that the metric itself, rather than nanoparticle delivery, was problematic [54].”
Joo, K. S., Kwon, I. A., Park, J.-Y., & Khang, D. (2026) · Materials Today Nano · doi:10.1016/j.mtnano.2026.100941
Next-Generation Nanomedicines: Integration of Nanodrug Carriers and Artificial Intelligence
Prakash, S., Madhavan, B., Kumar, S. C., Lincy, M. J. A., Nangan, S., & Pillai, B. M. (2026) · Russian Journal of Physical Chemistry A · doi:10.1134/s0036024426701591
Singaravelu, S., Balu, R., Senthilkumar, C., & Jayaprakash, J. (2026) · Frontiers in Biomaterials Science · doi:10.3389/fbiom.2026.1912922
Drug Delivery With Metal–Organic Frameworks
Tarabay, N. W., Evtushenko, A. S., Kiapi, M. R. A., Chen, X., Caamaño, K., Fruk, L., & Fairen‐Jiménez, D. (2026) · Angewandte Chemie Novit · doi:10.1002/anov.70037
AlSuhaimi, S. A., AlSaedi, D. S., Abdulrazaq, R. K., & AlSuhaimi, A. O. (2026) · Next Nanotechnology · doi:10.1016/j.nxnano.2026.100802
Sescu, V. A., Filipescu, A., Solomon-Condriuc, I. P., Burac, M., Scripcariu, I. S., Socolov, D. G., Socolov, R. V., & Cărăuleanu, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101218
Nakazaki, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188308
“SCI studies should report the fraction of the injected dose that reaches the cord together with a blood-normalized exposure ratio because the dose fraction alone correlates poorly with standard pharmacokinetic measures [105].”
Stealth Strategies for Cancer Nanomedicine: A Review of Immune Evasion and Tumor Targeting
Chitra, A., & Chetty, S. S. (2026) · Future Pharmacology · doi:10.3390/futurepharmacol6040052
Bolaños, K., Montanox, Y., León, D., Jara-Guajardo, P., Contreras, P., Silva, D., Riveros, A. L., Donoso-González, O., Melo, F., Araya, E., et al. (2026) · Materials & Design · doi:10.1016/j.matdes.2026.117177
Precision engineering of nanocarriers for transport across complex biological barriers
Acharya, R., Komedchikova, E., Choi, Y., Yang, J., Kim, J., Son, J., Jang, J., Lee, H., Kadonosono, T., & 최종훈 (2026) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2026.100691
“…over more than a decade of formulation development (Wilhelm et al., 2016), although subsequent reanalysis using classical pharmacokinetic metrics has argued that percentage-of-injected-dose comparisons understate the pzharmacological advantage conferred by nanocarriers (Price et al., 2020).”
González, C. C. (2026) · Nano Futures · doi:10.1088/2399-1984/aeb636
“A subsequent reanalysis of the same datasets argued that this metric substantially understates delivery, reporting roughly 100-fold higher relative tumor exposure when classical pharmacokinetic endpoints such as the tumor-to-blood area-under-the-curve ratio are used instead [5].”
Karim, A., Sutikno, Syarif, A. M., & Cheol, J. I. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1919132
Drug Delivery Systems for Breast Cancer Treatment: From Design Principles to Clinical Translation
Sescu, V. A., Condriuc, I. P. S., Spridon, L. G., Cadinoiu, A. N., Miron, L., Atanase, L. I., Matasariu, D. R., Socolov, D. G., & Cărăuleanu, A. (2026) · Cancers · doi:10.3390/cancers18203393
Merecz-Sadowska, A., Kowalczyk, T., Tylkowski, B., Picot, L., Zajdel, R., & Sitarek, P. (2026) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2026.218690
Prioritizing Impact: Cancers for Nanomedicine
Straehla, J. P. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.6c00236
Autonomous Nanomedicine: Closing the Biological Validation Gap
Lin, Y.-C., & Komperda, I. (2026) · Exploration · doi:10.1002/exp2.70228
Metadata
- Authors
- Price, L. S. L., Stern, S. T., Deal, A. M., Kabanov, A. V., & Zamboni, W. C.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Nanotechnology Characterization Lab (NCL), Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
- Corresponding author
- Zamboni, William C.
- Venue
- Science Advances
- Published
- 2020-07-17
- Volume
- 6
- Issue
- 29
- Pages
- eaay9249-eaay9249
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC7439617
- OpenAlex
- W3042603832
- Cited by
- 128
- References
- 21
- Citations by year
- 2026: 20 · 2025: 14 · 2024: 21 · 2023: 24 · 2022: 19 · 2021: 21 · 2020: 9
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Carolina Center of Cancer Nanotechnology Excellence, University of North Carolina - Chapel Hill (1U54CA19899-01 Pilot Grant)
- Carolina Cancer Nanotechnology Training Program (1T32CA196589, R01CA184088)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Keywords
- pharmacokinetics, tumor biodistribution, nanotherapeutics, reanalysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.